File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Clinical applicability of the ATP cell viability assay as a predictor of chemoresponse in platinum-resistant epithelial ovarian cancer using nonsurgical tumor cell samples

TitleClinical applicability of the ATP cell viability assay as a predictor of chemoresponse in platinum-resistant epithelial ovarian cancer using nonsurgical tumor cell samples
Authors
KeywordsATP cell viability assay
Chemosensitivity
Chemotherapy
Platinum-resistant epithelial ovarian cancer
Recurrent ovarian cancer
Issue Date2000
PublisherAcademic Press. The Journal's web site is located at http://www.elsevier.com/locate/ygyno
Citation
Gynecologic Oncology, 2000, v. 76 n. 3, p. 405-408 How to Cite?
AbstractObjectives. There is no basis for choosing one chemotherapy over another in platinum-resistant epithelial ovarian cancer based on published response rates. This study explores the feasibility and accuracy of the ATP cell viability assay (ATP-CVA) in predicting chemoresponse in these difficult situations to choose the most appropriate drug for treatment. Methods. Predominantly nonsurgical tumor samples for histological proof of recurrence were tested against a panel of drugs for salvage chemotherapy. Clinicians were blinded to the test results. Patient responses were evaluated after a minimum of three cycles of single-agent chemotherapy and correlated with test results. Results. The evaluability rate was 85% (5 of 33 contaminated). The majority (24) were obtained by abdominal paracentesis and trucut biopsy. Of the 28 successful assays, 8 were excluded from analysis because four chose not to have chemotherapy and four withdrew after fewer than three cycles because of unacceptable side effects. The overall response rate to salvage chemotherapy was 15%. The sensitivity was 100% and specificity 82%. Resistance was correctly predicted in 100% and response correctly predicted in 50%. The outcomes of 17 of 20 patients were predicted correctly, giving an accuracy of 85%. Conclusions. It is feasible to test nonsurgical tumor specimens in recurrent cancer. The ATP-CVA correctly identified a group of patients with a 50% chance of response to salvage chemotherapy. This information may be useful in the decision-making process. A prospective, randomized study will be done to confirm these results. (C) 2000 Academic Press.
Persistent Identifierhttp://hdl.handle.net/10722/87485
ISSN
2015 Impact Factor: 4.198
2015 SCImago Journal Rankings: 2.284
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorNg, TYen_HK
dc.contributor.authorNgan, HYSen_HK
dc.contributor.authorCheng, DKLen_HK
dc.contributor.authorWong, LCen_HK
dc.date.accessioned2010-09-06T09:30:16Z-
dc.date.available2010-09-06T09:30:16Z-
dc.date.issued2000en_HK
dc.identifier.citationGynecologic Oncology, 2000, v. 76 n. 3, p. 405-408en_HK
dc.identifier.issn0090-8258en_HK
dc.identifier.urihttp://hdl.handle.net/10722/87485-
dc.description.abstractObjectives. There is no basis for choosing one chemotherapy over another in platinum-resistant epithelial ovarian cancer based on published response rates. This study explores the feasibility and accuracy of the ATP cell viability assay (ATP-CVA) in predicting chemoresponse in these difficult situations to choose the most appropriate drug for treatment. Methods. Predominantly nonsurgical tumor samples for histological proof of recurrence were tested against a panel of drugs for salvage chemotherapy. Clinicians were blinded to the test results. Patient responses were evaluated after a minimum of three cycles of single-agent chemotherapy and correlated with test results. Results. The evaluability rate was 85% (5 of 33 contaminated). The majority (24) were obtained by abdominal paracentesis and trucut biopsy. Of the 28 successful assays, 8 were excluded from analysis because four chose not to have chemotherapy and four withdrew after fewer than three cycles because of unacceptable side effects. The overall response rate to salvage chemotherapy was 15%. The sensitivity was 100% and specificity 82%. Resistance was correctly predicted in 100% and response correctly predicted in 50%. The outcomes of 17 of 20 patients were predicted correctly, giving an accuracy of 85%. Conclusions. It is feasible to test nonsurgical tumor specimens in recurrent cancer. The ATP-CVA correctly identified a group of patients with a 50% chance of response to salvage chemotherapy. This information may be useful in the decision-making process. A prospective, randomized study will be done to confirm these results. (C) 2000 Academic Press.en_HK
dc.languageengen_HK
dc.publisherAcademic Press. The Journal's web site is located at http://www.elsevier.com/locate/ygynoen_HK
dc.relation.ispartofGynecologic Oncologyen_HK
dc.subjectATP cell viability assayen_HK
dc.subjectChemosensitivityen_HK
dc.subjectChemotherapyen_HK
dc.subjectPlatinum-resistant epithelial ovarian canceren_HK
dc.subjectRecurrent ovarian canceren_HK
dc.titleClinical applicability of the ATP cell viability assay as a predictor of chemoresponse in platinum-resistant epithelial ovarian cancer using nonsurgical tumor cell samplesen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0090-8258&volume=76&spage=405&epage=408&date=2000&atitle=Clinical+applicability+of+the+ATP+cell+viability+assay+as+a+predictor+of+chemoresponse+in+platinum-resistant+epithelial+ovarian+cancer+using+nonsurgical+tumor+cell+samplesen_HK
dc.identifier.emailNgan, HYS:hysngan@hkucc.hku.hken_HK
dc.identifier.authorityNgan, HYS=rp00346en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1006/gyno.1999.5698en_HK
dc.identifier.pmid10684718en_HK
dc.identifier.scopuseid_2-s2.0-0034092010en_HK
dc.identifier.hkuros56278en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0034092010&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume76en_HK
dc.identifier.issue3en_HK
dc.identifier.spage405en_HK
dc.identifier.epage408en_HK
dc.identifier.isiWOS:000085784900022-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridNg, TY=7402229853en_HK
dc.identifier.scopusauthoridNgan, HYS=34571944100en_HK
dc.identifier.scopusauthoridCheng, DKL=7402806161en_HK
dc.identifier.scopusauthoridWong, LC=7402092003en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats